The coronavirus disease 2019 (COVID-19) pandemic evolves rapidly as a global emergency that demands extensive vaccinations against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) to establish an immune barrier to protect against infection/disease efficiently and economically. Up to the early November of 2021, a total of 2.3 billion doses of SARS-CoV-2 vaccination have been performed in China. Recently, children at the age of 3 to 17 have also been introduced to implement SARS-CoV-2 vaccination continuously. Allergic rhinitis (AR) is a common pediatric chronic inflammation in respiratory tract, and nasal steroid and antihistamine have been extensively used to treat AR as well as allergen-specific immunotherapy (AIT) which has been used to establish immune tolerance. In order to implement SARS-CoV-2 vaccination in children with AR, the Oriental Allergy Alliance (OAA) specifically organized an expert panel which enrolls a group of well-known experts in the fields of Rhinology, Allergy and Pediatrics to compile this document on the basis of clinical experience and evidences. The document aims to provide practical recommendations for safe and effective SARS-CoV-2 vaccination in AR children with or without AIT.